Market Overview

Morning Market Movers

Related ALNY
Alnylam Reports Positive Initial Clinical Results for ALN-AS1, an Investigational RNAi Therapeutic Targeting Aminolevulinic Acid Synthase 1 (ALAS1) for the Treatment of Acute Hepatic Porphyrias
Top 4 Mid-Cap Stocks In The Biotechnology Industry With The Highest EPS Growth Forecast For Next 5 Years
Sanofi Opts into Alnylam's ALN-AT3 Hemophilia Program (Zacks)
Related MRK
Roth Capital Upgrades ANI Pharmaceuticals To Buy On Valuation
Merck Announces New Data from KEYNOTE-028 Trial Evaluating KEYTRUDA Across Range of Cancer Types, Presented at 2015 ECC
Alexion, Vertex Steal Mo Stanley's Eyes From Gilead (Investor's Business Daily)

Alnylam Pharmaceuticals (NASDAQ: ALNY) rose 34.16% to $88.83 after the company reported that it has acquired investigational RNAi Therapeutic assets from Merck (NYSE: MRK). Genzyme and Alnylam expanded their collaboration on rare genetic diseases.

Rexahn Pharmaceuticals (NYSE: RNN) jumped 33.77% to $1.53. Rexahn Pharmaceuticals shares have jumped 235.29% over the past 52 weeks, while the S&P 500 index has gained 25.27% in the same period.

Rosetta Genomics (NASDAQ: ROSG) moved up 33.23% to $4.25 after the company reported that it has signed a master service provider agreement with a major global biopharmaceutical company.

Teche Holding Company (NYSE: TSH) shares jumped 28.44% to $70.00 after IBERIABANK (NASDAQ: IBKC) announced an agreement to acquire Teche Holding.

Posted-In: market moversNews Intraday Update Markets Movers


Related Articles (ALNY + IBKC)

View Comments and Join the Discussion!

Get Benzinga's Newsletters